TY - JOUR
AU - Jorde, Ulrich P.
AB - Endocrine (2022) 75:654–658 https://doi.org/10.1007/s12020-021-02929-1 RESEARCH LETTER Healthcare disparities in heart failure patients (with and without type 2 diabetes) and use of sodium glucose co-transport inhibitors (SGLT2-i) 1 1 2 3 2 ● ● ● ● ● Shivank Madan Muhammad Farooq Karim Diab Angelos A. Melainis Katherine E. DiPalo 4 1 1 ● ● Jill P. Crandall Carlos J. Rodriguez Ulrich P. Jorde Received: 28 June 2021 / Accepted: 26 October 2021 / Published online: 9 November 2021 © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 Acronyms and abbreviations initiative to understand and address the unique challenges HF Heart Failure faced by socioeconomically disadvantaged HF-patient SGLT2-I Sodium-glucose-cotransporter-2 inhibitors population in the Bronx, we sought to phenotype the LVEF Left ventricular ejection fraction burden of diabetes, and understand any disparities LVH Left-ventricular hypertrophy including the use of SGLT2-i. OR Odds-ratio SDoH Social determinants of health Methods Co-existence of diabetes and heart failure (HF) compli- cates patient-care including medication adherence, diet/ Detailed information was collected from medical records lifestyle changes, care-coordination across specialties, for consecutive adult (≥18 years) patients with HF and increased out-of-pocket costs, contributing to worse [reduced and preserved left-ventricular ejection fraction 
TI - Healthcare disparities in heart failure patients (with and without type 2 diabetes) and use of sodium glucose co-transport inhibitors (SGLT2-i)
JF - Endocrine
DO - 10.1007/s12020-021-02929-1
DA - 2022-02-01
UR - https://www.deepdyve.com/lp/springer-journals/healthcare-disparities-in-heart-failure-patients-with-and-without-type-FS0KNALGlI
SP - 654
EP - 658
VL - 75
IS - 2
DP - DeepDyve
ER -